$CCCC News

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 Therapeutics

Roche and C4 Therapeutics to advance degrader-antibody conjugates research

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics shares are trading higher after the company announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate modality.

C4 Therapeutics shares are trading higher after the company announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate modality.